Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study

Authors :: Bang-Mao Wang
Zhixiang Zhuang
Feng Wang
T. Liu
Rui-Hua Xu
Feng Bi
Helong Zhang
Xianglin Yuan
Ying Yuan
Yanhong Deng
Yuxian Bai
Ying Wang
Wangjun Liao
Kangsheng Gu
Jianming Xu
Huiyan Luo
Source :: Journal of Clinical Oncology. 36:4045-4045
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 4045Background: Gastric cancer (GC) is one of the most common tumors in China. The ToGA study has shown trastuzumab in combination with fluoropyrimidine plus cisplatin prolonged overall survival (O...

Subjects :: Cisplatin
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Cancer
medicine.disease
First line treatment
Capecitabine
Docetaxel
Trastuzumab
Internal medicine
medicine
Open label
business
medicine.drug
Single Arm Study

Full Text Access

Tools